OPEN SANS HH STACKED_2.jpg
Two New Solutions from Hemex Health Empower More Clinicians and Health Workers to Test for Iron Deficiency Anaemia and Sickle Cell Disease
14 nov. 2024 08h00 HE | Hemex Health
NAGPUR, India, Nov. 14, 2024 (GLOBE NEWSWIRE) -- At the Haematocon 2024 conference in Nagpur, India, Hemex Health announced new product offerings for the Company’s Gazelle™ Diagnostic Device that...
OPEN SANS HH STACKED_2.jpg
Researchers Find Gazelle™ Hb Variant Test Offers Accuracy and Accessibility for Newborn Sickle Cell Disease Screening and Premarital Screening for Beta Thalassemia and Sickle Cell Disease
07 oct. 2024 05h00 HE | Hemex Health
In Brief: Findings from studies in Türkiye and Ghana presented at ASCAT 19th Annual Scientific Conference demonstrate that the Gazelle™ Hb Variant Test is an effective tool for accurate and...
OPEN SANS HH STACKED_2.jpg
New Research Confirms Hb Variant Test for Sickle Cell, Gazelle™, Useful for Screening and Tracking Treatment Management in Remote Settings, Advancing Doctors’ Abilities to Better Detect and Manage the Disease
20 juin 2024 08h00 HE | Hemex Health
PORTLAND, Ore. and ACCRA, Ghana, June 20, 2024 (GLOBE NEWSWIRE) -- Hemex Health announced that the results of two investigations into the effectiveness of their Gazelle™ point-of-care Hb Variant...
The Gazelle Hb Variant Test
Study of First Affordable and Rapid Test for Beta Thalassemia Performs at 99% Accuracy in Diagnosing the Blood Disorder
05 févr. 2024 08h00 HE | Hemex Health
A clinical study demonstrated high accuracy for Hemex Health's beta thalassemia test. It is the only beta thal test for point of care.
NMDP-BTM_Dual_2_Color_BlueGreen_Logo_RGB_2000x542 (1).png
Sickle Cell Warrior Program from The National Marrow Donor Program® (NMDP)/Be The Match® Expands Access to Bone Marrow Transplant as a Curative Treatment
31 août 2023 09h00 HE | Be The Match
During Sickle Cell Awareness Month, NMPD/Be The Match reminds individuals to visit SickleCellConnect.com to access essential resources, learn more about Sickle Cell Disease, and join the Be The Match...
NMDP-BTM_Dual_2_Color_BlueGreen_Logo_RGB_2000x542 (1).png
Be The Match® Celebrates One Thousand “Get in the Game” Life-Saving Donors!
06 juin 2023 08h00 HE | Be The Match
MINNEAPOLIS, June 06, 2023 (GLOBE NEWSWIRE) -- Be The Match®, a global leader working to save lives through cellular therapy, today celebrates 1,000 blood stem cell or marrow donors through the “Get...
Featured Image for Experimental Biology and Medicine
Pain Intensity in Sickle Cell Disease
14 nov. 2022 10h00 HE | Experimental Biology and Medicine
WASHINGTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 247, Issue 17, September, 2022) improves our understanding of pain phenotypes...
Inserting the Hb variant cartridge into the Gazelle Reader for analysis
Hemex Health announces breakthrough measurement capability for clinicians monitoring sickle cell disease therapy
08 mai 2022 06h00 HE | Hemex Health
PORTLAND, Ore. and MUMBAI, India, May 08, 2022 (GLOBE NEWSWIRE) -- Hemex Health, a Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test,...
6th Leadership Summit - Sickle Cell Consortium
Sickle Cell Consortium Hosts 6th Annual Leadership Summit - Advocacy & Capacity-Building in the Digital Age
25 avr. 2022 08h00 HE | Sickle Cell Consortium
ATLANTA, April 25, 2022 (GLOBE NEWSWIRE) -- The Sickle Cell Consortium hosts the 6th Annual Leadership Summit and General Assembly of Patients, Caregivers, and Community-Based Organizations (CBOs)...
Imara-Logo-Color-RGB.jpg
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
05 avr. 2022 06h45 HE | Imara, Inc.
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat...